BioNTech, ADR
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
Investor's Business Daily on MSN4d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A RecoveryBioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
Zacks.com on MSN8d
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...
BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...
The University of Pennsylvania has sued German biotechnology firm BioNTech in Pennsylvania federal court, accusing the ...
It’s been over four years since the beginning of the COVID-19 pandemic. And since then, the virus has changed substantially.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback